Intravenous Thrombolysis after Dabigatran Reversal with a Specific Antidote Idarucizumab

1. Škoda O, Herzig R, Mikulík R, et al. Klinický standard pro diagnostiku a léčbu pacientů s ischemickou cévní mozkovou příhodou a s tranzitorní ischemickou atakou – verze 2016. Cesk Slov Neurol N 2016;79/112(3):351–63.

2. Neumann J, Tomek A, Školoudík D, et al. Doporučený postup pro intravenózní trombolýzu v léčbě akutního mozkového infarktu – verze 2014. Cesk Slov Neurol N 2014;77/110(3):381–5.

3. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al.; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2016;47(2):581–641. doi: 10.1161/STR.0000000000000086.

4. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121(18):3554–62. doi: 10.1182/blood-2012-11-468207.

5. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386(9994):680–90. doi: 10.1016/S0140-6736(15)60732-2.

6. Pollack CV jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373(6):511–520. doi: 10.1056/NEJMoa1502000.

7. Státní ústav pro kontrolu léčiv. SPC přípravku Praxbind^®. [cit. 2017 20 Čer]. Dostupné z URL: http://www.sukl.cz/modules/medication/detail.php?code=0209048&tab=texts.

8. Berrouschot J, Stoll A, Hogh T, et al. Intravenous Thrombolysis with Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant after Antagonization with Idarucizumab. Stroke 2016;47(7):1936–8. doi: 10.1161/STROKEAHA.116.013550.

9. Schäfer N, Müller A, Wüllner U. Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab – a Case Report. J Stroke Cerebrovasc Dis 2016;25(8):e126–7. doi: 10.1016/j.jstrokecerebrovasdis.2016.05.006.

10. Kafke W, Kraft P. Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report. Case Rep Neurol 2016;8(2):140–4. doi: 10.1159/000447531.

11. Gawehn A, Ayari Y, Heuschkel C, et al. Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report. J Med Case Rep 2016;10(1):269.

12. Schulz JG, Kreps B. Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke. J Neurol Sci 2016;370:44. doi: 10.1016/j.jns.2016.09.010.

13. Mutzenbach JS, Pikija S, Otto F, et al. Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab –a case report. Ann Clin Transl Neurol 2016;3(11):889–92. doi: 10.1002/acn3.346.

14. Diener HC, Bernstein R, Butcher K, et al. Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion. Int J Stroke 2017;12(1):9–12. doi: 10.1177/1747493016669849.

15. FDA approved drugs database Praxbind prescribing information. Boehringer Ingelheim International GmbH; 2015. [accessed 2017 20 Jun]. Available from URL:

http://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2015/761025lbl.Pdf.

16. van Ryn J, Schurer J, Fischer D. Abstract wp73: No influence of Dabigatran or its specific reversal agent, Idarucizumab, on rtpa-induced thrombolysis of clots in human plasma: an in vitro study Stroke 2016;47:AWP73.